Genelux (NASDAQ:GNLX) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Genelux (NASDAQ:GNLX) in a research report released on Tuesday morning,Benzinga reports. They currently have a $30.00 price objective on the stock.

Genelux Stock Performance

Shares of GNLX stock opened at $3.40 on Tuesday. Genelux has a fifty-two week low of $1.60 and a fifty-two week high of $6.50. The company has a market cap of $117.43 million, a PE ratio of -3.58 and a beta of -1.41. The stock’s fifty day moving average price is $4.02 and its two-hundred day moving average price is $3.09.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of GNLX. Apollon Wealth Management LLC grew its holdings in shares of Genelux by 20.4% during the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock valued at $40,000 after purchasing an additional 2,857 shares during the last quarter. LifeSteps Financial Inc. grew its stake in shares of Genelux by 11.1% during the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock worth $205,000 after buying an additional 8,715 shares during the last quarter. Brown Brothers Harriman & Co. increased its holdings in shares of Genelux by 76.2% during the third quarter. Brown Brothers Harriman & Co. now owns 21,075 shares of the company’s stock worth $50,000 after buying an additional 9,114 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Genelux in the 4th quarter valued at $25,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Genelux during the 4th quarter valued at $41,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.